CL2017002445A1 - Variantes de pertuzumab y su evaluación. - Google Patents

Variantes de pertuzumab y su evaluación.

Info

Publication number
CL2017002445A1
CL2017002445A1 CL2017002445A CL2017002445A CL2017002445A1 CL 2017002445 A1 CL2017002445 A1 CL 2017002445A1 CL 2017002445 A CL2017002445 A CL 2017002445A CL 2017002445 A CL2017002445 A CL 2017002445A CL 2017002445 A1 CL2017002445 A1 CL 2017002445A1
Authority
CL
Chile
Prior art keywords
pertuzumab
variants
compositions
molecular weight
weight species
Prior art date
Application number
CL2017002445A
Other languages
English (en)
Inventor
Lynn A Gennaro
Yung-Hsiang Kao
Yonghua Zhang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50694078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002445(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2017002445A1 publication Critical patent/CL2017002445A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44747—Composition of gel or of carrier mixture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>La presente solicitud describe variantes de pertuzumab. En particular, se revela: una variante de cisteína no apareada que comprende cisteinas Cys23/Cys88 no apareadas en uno o ambos dominios variables livianas de pertuzumab, una variante afucosilada de pertuzumab, una especie de bajo peso molecular (LMWS) de pertuzumab, y una especie de elevado peso molecular (HMWS) de pertuzumab. La solicitud describe además las variantes aisladas, composiciones, composiciones farmacéuticas, y articulos de fabricación que comprenden las variantes, así como también métodos para preparar y caracterizar las variantes y sus composiciones.</p>
CL2017002445A 2013-04-16 2017-09-28 Variantes de pertuzumab y su evaluación. CL2017002445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361812603P 2013-04-16 2013-04-16

Publications (1)

Publication Number Publication Date
CL2017002445A1 true CL2017002445A1 (es) 2018-03-16

Family

ID=50694078

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2015003049A CL2015003049A1 (es) 2013-04-16 2015-10-15 Variantes de pertuzumab y su evaluación
CL2017002445A CL2017002445A1 (es) 2013-04-16 2017-09-28 Variantes de pertuzumab y su evaluación.
CL2019002244A CL2019002244A1 (es) 2013-04-16 2019-08-08 Variantes de pertuzumab y su evaluación. (divisional solicitud 201702445)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015003049A CL2015003049A1 (es) 2013-04-16 2015-10-15 Variantes de pertuzumab y su evaluación

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019002244A CL2019002244A1 (es) 2013-04-16 2019-08-08 Variantes de pertuzumab y su evaluación. (divisional solicitud 201702445)

Country Status (25)

Country Link
US (8) US9815904B2 (es)
EP (3) EP4483964A3 (es)
JP (2) JP2016522176A (es)
KR (2) KR20200085942A (es)
CN (1) CN105121471A (es)
AR (1) AR095863A1 (es)
AU (3) AU2014254086B2 (es)
BR (1) BR112015024926A2 (es)
CA (2) CA3071678A1 (es)
CL (3) CL2015003049A1 (es)
CR (1) CR20150576A (es)
EA (1) EA201591643A1 (es)
HK (1) HK1211948A1 (es)
IL (2) IL241103B (es)
MA (1) MA38567A1 (es)
MX (2) MX368259B (es)
MY (1) MY173295A (es)
NZ (2) NZ751877A (es)
PE (3) PE20211214A1 (es)
PH (1) PH12015502382A1 (es)
RU (2) RU2737727C2 (es)
SG (3) SG10201911353WA (es)
TW (1) TWI554284B (es)
WO (1) WO2014172371A2 (es)
ZA (1) ZA201506594B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
JP6914336B2 (ja) * 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018200505A1 (en) * 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
WO2019055631A1 (en) 2017-09-13 2019-03-21 Mayo Foundation For Medical Education And Research IDENTIFICATION AND MONITORING OF ACID HYDROLYSIS PRODUCTS OF IMMUNOGLOBULIN HEAVY CHAINS
JP7259778B2 (ja) 2020-01-31 2023-04-18 トヨタ自動車株式会社 車両、及び自動運転システム
EP3892989A1 (en) * 2020-04-07 2021-10-13 Ares Trading S.A. Capillary gel electrophoresis and its use with complex biological molecules
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
CN113999313A (zh) * 2020-07-28 2022-02-01 百奥泰生物制药股份有限公司 抗her2抗体及其应用
CN113189184B (zh) * 2021-04-28 2022-09-09 浙江大学 含有半胱氨酸的毛细管凝胶电泳样品缓冲液
US20240238440A1 (en) 2021-04-29 2024-07-18 Hyslink Therapeutics Preparation method for and application of antibody conjugated drug
IL311003A (en) * 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
KR102511384B1 (ko) 2022-04-14 2023-03-16 지용환 곡물의 손상을 줄일 수 있는 도정기
WO2025021118A1 (zh) * 2023-07-25 2025-01-30 海南先声再明医药股份有限公司 配体-药物偶联物及其偶联连接子
GB202313175D0 (en) 2023-08-30 2023-10-11 Univ Oxford Innovation Ltd A bivalent polypeptide scaffold and uses thereof

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003357A1 (en) 1984-01-30 1985-08-01 Icrf Patents Ltd. Improvements relating to growth factors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0474727B1 (en) 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ES2293661T3 (es) 1996-11-27 2008-03-16 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteinas a.
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
PT1064027E (pt) 1998-03-27 2008-09-29 Genentech Inc Sinergismo de ligando de apo-2 e anticorpo anti-her-2
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE60033658T2 (de) 1999-06-25 2007-11-22 Genentech, Inc., South San Francisco Behandlung von prostata-krebs mit anti-erbb2 antikörpern
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20200048362A1 (en) 2000-03-16 2020-02-13 Immunogen, Inc. Methods of treatment using anti-erbb antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
EP1345968A2 (en) 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
DK1358318T3 (da) * 2001-02-07 2007-01-02 Wilex Ag Hybridomcellelinje G250 og dens anvendelse til frembringelse af monoklonale antistoffer
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
PT1543038T (pt) 2002-09-11 2017-07-07 Genentech Inc Purificação de proteína
EP1572972A4 (en) 2002-11-21 2007-11-21 Genentech Inc THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック， インコーポレイテッド プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
EP1827603A2 (en) 2004-12-13 2007-09-05 F. Hoffmann-Roche AG Novel pharmaceutical composition containing at least one dolastatin 10 derivative
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
US20060204505A1 (en) 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007259171A1 (en) 2006-06-05 2007-12-21 F. Hoffmann-La Roche, Ag Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
US8015939B2 (en) 2006-06-30 2011-09-13 Asml Netherlands B.V. Imprintable medium dispenser
AU2007287794B2 (en) 2006-08-21 2013-03-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-VEGF antibody
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
PL2132230T3 (pl) * 2007-03-22 2014-09-30 Genentech Inc Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną
EP1997534A1 (en) 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
AU2008258859A1 (en) 2007-06-06 2008-12-11 F.Hoffmann-La Roche Ag Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
EP2586788B1 (en) 2007-07-09 2017-11-29 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
HUE024877T2 (en) 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
MX2010008364A (es) * 2008-01-30 2010-08-23 Abbott Lab Composiciones y metodos para cristalizar fragmentos de anticuerpo.
CL2009000545A1 (es) 2008-03-06 2010-10-15 Genentech Inc Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
US9235334B2 (en) 2008-05-09 2016-01-12 Genesis Industries, Llc Managing landbases and machine operations performed thereon
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011069074A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
PH12012501157A1 (en) * 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012078771A1 (en) 2010-12-09 2012-06-14 Genentech, Inc. Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
RU2013139260A (ru) * 2011-01-28 2015-03-10 Нэшнл Рисеч Каунсил Оф Канада Конструирование иммуноглобулиновых доменов
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
BR112016024789A2 (pt) 2014-04-25 2017-10-24 Genentech Inc métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
EP3534948A1 (en) 2016-11-04 2019-09-11 Genentech, Inc. Treatment of her2-positive breast cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
HRP20260181T1 (hr) 2017-10-20 2026-03-27 BioNTech SE Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
AU2021308283A1 (en) 2020-07-14 2023-02-02 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
MX2023006793A (es) 2020-12-11 2023-06-20 Genentech Inc Tratamientos conjuntos para tratamiento de cancer her2.
TW202400230A (zh) 2022-03-14 2024-01-01 美商建南德克公司 乳癌的組合療法

Also Published As

Publication number Publication date
CA2907776C (en) 2020-04-14
RU2737727C2 (ru) 2020-12-02
US20230047103A1 (en) 2023-02-16
MX2019005151A (es) 2022-06-27
MX368259B (es) 2019-09-25
US20180037662A1 (en) 2018-02-08
US20190345258A1 (en) 2019-11-14
PH12015502382A1 (en) 2016-02-22
EP4483964A2 (en) 2025-01-01
JP2020015719A (ja) 2020-01-30
US20140308277A1 (en) 2014-10-16
TW201442725A (zh) 2014-11-16
US12145998B2 (en) 2024-11-19
PE20260743A1 (es) 2026-03-31
SG10201706045RA (en) 2017-08-30
AU2018241141A1 (en) 2018-10-25
US20200157238A1 (en) 2020-05-21
EP4483964A3 (en) 2025-04-30
AU2019253804A1 (en) 2019-11-14
EP2986643A2 (en) 2016-02-24
US20250084181A1 (en) 2025-03-13
KR20200085942A (ko) 2020-07-15
EP3800204A1 (en) 2021-04-07
EA201591643A1 (ru) 2016-02-29
JP2016522176A (ja) 2016-07-28
US9815904B2 (en) 2017-11-14
ZA201506594B (en) 2018-11-28
TWI554284B (zh) 2016-10-21
AU2014254086A1 (en) 2015-10-08
RU2015141520A (ru) 2017-05-22
CL2019002244A1 (es) 2019-11-29
MX2015013898A (es) 2016-07-08
MY173295A (en) 2020-01-14
CR20150576A (es) 2015-11-20
HK1211948A1 (en) 2016-06-03
AU2018241141B2 (en) 2019-11-07
WO2014172371A2 (en) 2014-10-23
AU2014254086B2 (en) 2018-07-05
KR20150143649A (ko) 2015-12-23
US20180037661A1 (en) 2018-02-08
CN105121471A (zh) 2015-12-02
BR112015024926A2 (pt) 2017-10-10
RU2019115089A (ru) 2019-06-11
US20180037660A1 (en) 2018-02-08
CL2015003049A1 (es) 2016-06-10
NZ712012A (en) 2020-04-24
PE20151769A1 (es) 2015-12-11
SG11201508536PA (en) 2015-11-27
IL241103B (en) 2020-07-30
IL241103A0 (en) 2015-11-30
IL275398A (en) 2020-07-30
AR095863A1 (es) 2015-11-18
EP4483964A8 (en) 2025-06-18
WO2014172371A3 (en) 2015-01-08
SG10201911353WA (en) 2020-02-27
US9969811B2 (en) 2018-05-15
CA2907776A1 (en) 2014-10-23
PE20211214A1 (es) 2021-07-05
CA3071678A1 (en) 2014-10-23
MA38567A1 (fr) 2017-09-29
NZ751877A (en) 2020-04-24

Similar Documents

Publication Publication Date Title
CL2019002244A1 (es) Variantes de pertuzumab y su evaluación. (divisional solicitud 201702445)
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
IL244713B (en) Silk potein fragment compositions and articles manufactured therefrom
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
HUE043697T2 (hu) Készítmények és eljárások HBV és TTR expressziójának modulálására
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX375102B (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
UY35661A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que lo s contienen
UY36949A (es) 2,4-dihidroxi-nicotinamidas como agonistas de apj
UY35305A (es) Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap)
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
CR20160448A (es) Nuevos derivados de piridina
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
PL3203977T3 (pl) Zestaw dermatologiczny zawierający kompozycje na bazie hibiskusa i oleju buriti
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
BR112017007173A2 (pt) &#34;cola biológica e seu uso como medicamento&#34;
NI201500172A (es) Composiciones farmacéuticas
PL408194A1 (pl) Kompozycja elastomerowa przeznaczona na wyroby o podwyższonej odporności na starzenie klimatyczne i promieniowanie UV